Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

Table 3 Trial efficacy endpoints: Key secondary outcomes

	Placebo	Imatinib	Effect size (95% CI)	p value
28-day mortality, n (%)	6 (18)	5 (15)	HR: 0.89 (0.39 to 2.07)	0.79
VFD, median days [IQR]*	19 [0, 24]	14 [0, 23]	HL: 1.00 (− 0.99 to 9.00)	0.29
Sensitivity analysis^†	19 [0, 24]	14 [0, 23]	HL: 1.00 (− 1.00 to 9.00)	0.36
Duration of ICU stay, median days [IQR]^‡	11 [6, 28]	23 [7, 28]	HL: 0.00 (− 0.11 to 0.00)	0.25
Hospital length of stay, median days [IQR]^‡	21 [13, 28]	28 [13, 28]	HL: − 2.00 (− 8.00 to 0.00)	0.20

Table summarizing the secondary outcomes at 28 days
HL Hodges—Lehmann estimator; HR Hazard ratio; ICU intensive care unit; IQR interquartile range; VFD ventilator-free days
^*Death penalized by assigning 0 days
^†Death penalized by assigning -1 days
^‡Death penalized by assigning 28 days

ISSN: 1364-8535